Skip to main content
Swedish Orphan Biovitrum logo

Swedish Orphan Biovitrum — Investor Relations & Filings

Ticker · SOBI ISIN · SE0000872095 LEI · 549300124Y3MQI87PT35 ST Manufacturing
Open in API
Filings indexed 892 across all filing types
Latest filing 2013-10-30 Interim / Quarterly Rep…
Country SE Sweden
Listing ST SOBI

About Swedish Orphan Biovitrum

https://www.sobi.com/en

Swedish Orphan Biovitrum (Sobi) is a specialized biopharmaceutical company dedicated to developing and delivering innovative treatments for rare and debilitating diseases. The company's primary focus is on the therapeutic areas of haematology and immunology, with a significant legacy and continued leadership in haemophilia care. Sobi addresses the high unmet medical needs of patients by advancing a pipeline of innovative medicines and working to expand patient access globally. The company's mission is to transform the lives of people affected by rare conditions through dedicated research, development, and global collaboration.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2013
Interim / Quarterly Report Classification · 100% confidence The document is a 'Report for the Third Quarter 2013' for Sobi. It contains comprehensive financial statements, business reviews, financial highlights, and an auditor's review of interim financial information. It is clearly a quarterly financial report, not an announcement or a summary, and it contains substantive financial data and analysis. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2013
2013-10-30 English
Sobi publicerar resultaten för det tredje kvartalet 2013
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive quarterly financial report ('Rapport för det tredje kvartalet 2013') for Swedish Orphan Biovitrum AB (Sobi). It contains detailed financial statements, management commentary ('VD har ordet'), operational highlights, and financial tables for the third quarter of 2013. It is not an announcement of a report, but the report itself, containing substantive financial data and analysis, thus fitting the definition of an Interim/Quarterly Report (IR). Q3 2013
2013-10-30 Swedish
Sobi publishes Report for the Third Quarter 2013
Interim / Quarterly Report Classification · 100% confidence The document is a 'Report for the Third Quarter 2013' for Sobi. It contains comprehensive financial statements, business reviews, financial highlights, and an auditor's review of interim financial information. It is clearly a quarterly financial report, not an announcement or a summary, and it contains substantive financial data and analysis. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2013
2013-10-30 English
Sobi lämnar in ansökan för en flytande formulering av Orfadin® till FDA
Regulatory Filings Classification · 99% confidence The document is a short press release dated October 29, 2013, announcing that Swedish Orphan Biovitrum AB (Sobi) has submitted an application for a liquid formulation of Orfadin to the FDA. It details the purpose of the new formulation (pediatric dosing) and provides background information on the drug and the company. This is a specific corporate announcement regarding regulatory interaction and product development, not a full financial report (like 10-K or IR), a transcript (CT), or a general regulatory filing (RNS). It is best classified as a general announcement related to corporate activities, but since it is not explicitly about management changes (MANG), financing (CAP), dividends (DIV), or legal matters (LTR), and it is a specific update on a product's regulatory status, it falls under the general category of regulatory/corporate news. Given the options, and since it is a specific, non-financial, non-legal, non-management update, the most appropriate category is the general fallback, Regulatory Filings (RNS), as it is a formal announcement to the market about a regulatory step taken.
2013-10-29 Swedish
Sobi submits application for Orfadin® oral suspension to FDA
Regulatory Filings Classification · 95% confidence The document is a short press release dated October 29, 2013, announcing that Sobi has submitted an application for Orfadin oral suspension to the FDA. It contains company background information and contact details but does not present comprehensive financial results (ruling out 10-K, AR, IR, ER, MRQ) or detailed management/governance information. It is a specific operational announcement regarding regulatory submission for a product. Since there is no specific category for 'Regulatory Submission Announcement' or 'Product Update', and it is not a standard financial filing, it falls best under the general 'Regulatory Filings' category, which serves as a fallback for miscellaneous regulatory announcements that don't fit the other specific codes (like DVA, DLST, LTR, etc.). Given its nature as a general corporate announcement related to regulatory activity, RNS is the most appropriate fit.
2013-10-29 English
Major Shareholding Notification 2013
Major Shareholding Notification Classification · 99% confidence The document explicitly details a change in shareholding percentage for 'Teachers Insurance and Annuity Association of America' concerning 'Swedish Orphan Biovitrum AB (publ)'. It specifies the 'Reason for major shareholding notification' and provides 'Before the transaction' and 'After the transaction' quantities and percentages, culminating in a 'Group total holdings' percentage of 4.962%. This content directly matches the definition of a Major Shareholding Notification.
2013-10-10 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.